Brief: Assembly Bio Announces Decision To Discontinue Clinical Development Of AbI-H2158

Assembly Biosciences

01/09/2021 21:21

Sept 1 (Reuters) - Assembly Biosciences Inc  ASMB.O :
    * ASSEMBLY BIO ANNOUNCES DECISION TO DISCONTINUE CLINICAL
DEVELOPMENT OF ABI-H2158
    * ASSEMBLY BIO - DECISION TO DISCONTINUE DEVELOPMENT OF
ABI-H2158
FOLLOWS OBSERVATION OF ELEVATEDALANINE TRANSAMINASE (ALT) LEVELS
IN PHASE 2 STUDY
    * ASSEMBLY BIOSCIENCES INC - COMPANY WILL FOCUS ON ADVANCING
ONGOING TRIPLE COMBINATION STUDIES AND EARLIER PIPELINE
CANDIDATES

Source text for Eikon:  ID:nGNX4VBRxt 
Further company coverage:  ASMB.O